Nant Holdingsip, LLC

Nantomics, LLC

Nantbio, Inc.

Chan Soon-shiong Nanthealth Foundation

Nantbioscience, Inc.

Nantneuro, LLC

Oleksandr V Buzko

Kayvan R Niazi

Shahrooz Rabizadeh

Justin Golovato

Patrick Soon-Shiong

Anne-Laure Le Ny

Stephen Charles Benz

Paul Weingarten

Heather McFarlane

Anne-Laure LeNy

Connie Tsai

Andrew Nguyen

Varghese John

Chunlin Tao

Barbara Jagodzinska

David T Ho

Patricia R Spilman

Anna B Juncker-Jensen

Dale Bredesen

Jay Gardner Nelson

Jay Nelson

Heather Mcfarlane

Niazi Kayvan

Anna Juncker-Jensen

Methods and compositions for preparation and use of recombinant viruses or other recombinant expression systems are presented in which neoepitopes are first identified in a patient- and cancer-specific manner and then further filtered by HLA-match to the patient. Selected neoepitopes are then expression using sequence elements that direct the expressed neoepitope to the HLA-type (MHC-I and/or MHC-II subtype) that has desirable affinity to the filtered neoepitope.

Compositions and methods for viral cancer neoepitopes

Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.

Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau

Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.

Compositions and methods of Rit1 inhibition

The invention relates to a method of modeling K-Ras proteins with one or more mutations that result in constitutive activity, and identifying compounds that inhibit interactions among activated K-Ras proteins and their upstream and downstream effectors.

Compositions and methods of targeting mutant K-Ras

Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

Compositions and methods of targeting mutant K-RAS

Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.

Compositions and methods of improved wound healing

Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5' and 3&#x2032;-UTR sequences of the viral genome.

Small molecule inhibitors of influenza A RNA-dependent RNA polymerase

Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.

Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Caionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.

Calcium flux agonists and methods therefor

Calcium flux agonists and methods thereof

Growing community of inventors

Oak Park, CA, United States of America

Oleksandr V Buzko